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IntroductionMutation of lymphoid progenitor cells in the bone marrow which induces excessive and uncontrolled lymphoid cell proliferation causes acute lymphoblastic leukemia (ALL).1 Acute lymphoblastic leukemia is the most common leukemia diagnosed in children with the highest prevalence of rate in children aged 2–5 years old and predominantly in boys.2,3,4 Twenty-six percent of all malignancy cases diagnosed in the USA in 2014 is acute lymphoblastic leukemia.3 It is also one of the malignancies with high incidence rate in Indonesia, as shown in Dr. Hasan Sadikin 
General Hospital reports where fifty-one new cases of ALL had been found in 2010–2011, 
while 76 new cases were found in 2014.5,6 It is known that half of the pediatric patients with malignancy in 2006 had been admitted to Dharmais National Cancer Hospital with advanced stage condition. Lack of knowledge about any signs or symptoms of the disease has been the cause of such conditions.7 Clinical features presenting in ALL are 
various. Generally, the first signs and symptoms 
are often non-specific which caused by anemia, such as irritability, anorexia, weakness, and pallor. Fever and infection might occur due to neutropenia, while thrombocytopenia might cause hemorrhages. Leukemic cells could 
infiltrate various organs resulting in other clinical features including hepatomegaly, splenomegaly, lymphadenopathy, and even 
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Abstract
Background: Acute lymphoblastic leukemia (ALL) is a disease caused by a mutation of lymphoid progenitor cells in bone marrow, that induces uncontrolled lymphoid cell proliferation. ALL is the most common type of leukemia in children. Various clinical and laboratory manifestation makes the diagnostic process more complicated. This study aimed to observe the clinical and laboratory manifestation of children with ALL in Dr. Hasan Sadikin General Hospital for diagnostic and assessment.
Methods: The design of this study was a descriptive cross-sectional with a total sampling method. Data of all children under 18 years old with ALL diagnosed in 2015 to 2017 were included. The diagnosis of 
ALL was confirmed by examination of hematology indices, peripheral blood smear, and bone marrow 
aspiration classified by FAB. Inaccessible or incomplete medical records were excluded.
Results: In total, 192 data of ALL patients were included. Most ALL patients predominantly occurred in boys (59.9%), and the age group of 1–5 years old (40.6%). The clinical manifestations were pallor (89.6%), hepatomegaly (79.7%) and fever (75%). Most patients experienced severe anemia with hemoglobin level <7g/dL (44.8%), leukocytosis >20.000 cells/mm3 (46.9%), severe thrombocytopenia with platelet count <20.000 cells/mm3 (51%), and blast cells count >50% (45.3%). Based on FAB 
classification, the majority of the patients were classified as ALL type L2 (65.6%).
Conclusions: Clinical and laboratory manifestation of ALL patients can be used as a parameter for diagnostic and assessment of severity. Earlier diagnosis would result in better prognosis and more precise treatment for ALL patients.
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nerve involvement.4
Diagnosis and classification ALL can be determined based on clinical and laboratory examination. Data supporting diagnosis can be obtained from peripheral blood smear examination or bone marrow aspiration.8 Early signs of ALL can be observed as abnormal blood examination, which is anemia, thrombocytopenia, and leukocytosis. Blast cells commonly found in the peripheral blood smear. Bone marrow aspiration acts as the gold standard in diagnosing ALL. When bone marrow aspiration result shows more than 5% of blast cells count, we can presume the patient 
as having leukemia; while for ALL definite diagnosis, more than 20% on blast cells count is needed. Differentiation of ALL and AML will be determined by cell morphology obtained 
from bone marrow aspiration classified based on French American British (FAB) 
classification. This classification depends on cell size, chromatin, nucleoli, and cytoplasm.4 
Classification based on the World Health Organization (WHO) can be done if the sample is examined using molecular method and then 
flow cytometri.9 Dr. Hasan Sadikin General Hospital’s procedure for diagnosing ALL consists of anamnesis, physical and laboratory examination such as hematology indices, peripheral blood smear, and bone marrow examination.5Data on clinical and laboratory manifestation of ALL in children in Dr. Hasan Sadikin General Hospital Bandung is still unknown. Aim of this study was to give more information on clinical and laboratory manifestation of ALL in children in Dr. Hasan Sadikin General Hospital Bandung. This information could help in detecting and diagnosing ALL leading to more precise treatment and better prognosis.
MethodsThe design of this study was a descriptive cross-sectional study. Data were obtained from inpatient Medical Record Unit Dr. Hasan Sadikin General Hospital Bandung during 2015–2017. Subjects were all medical records of children who had been diagnosed with ALL 
for the first time in Dr. Hasan Sadikin General 
Hospital and confirmed with hematology examination, peripheral blood smear, and bone marrow aspiration, with total sampling method. Exclusion criteria were inaccessible or incomplete medical records. Clinical manifestations data was collected, including pallor, fever, hemorrhage, seizure, infiltrative presentation (hepatomegaly, splenomegaly measured by schuffner line which depends on enlargement of spleen measured from left costal margin to right anterior superior iliac spine, and lymphadenopathy); as well as and laboratory data, including hematological examination (hemoglobin, leukocyte, thrombocyte), peripheral blood smear for blast cell counting, and bone marrow aspiration to classify ALL 
based on FAB classification, depending on morphological including cell size, chromatin, nucleoli, and cytoplasm.4Data were obtained from the medical record after Ethical Clearance was granted, issued by the Research Ethics Committee of Universitas Padjajaran Bandung (No. 219/UN6.KEP/EC/2018) and Research Licensing Letter issued by the Research Ethics Commitee of Dr. Hasan Sadikin General Hospital Bandung (No. LB.02.01/X.2.2.1/9373/2018.) Data were presented in tables.
Table 1 Characteristics of Acute Lymphoblastic Leukemia Patients
Total
N %Gender     Boy 115 59.9     Girl 77 40.1Age     < 1 year old 7 8.9     > 1–5 years old 78 40.6     > 5–10 years old 56 29.2     > 10–18 years old 41 21.4
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ResultsThere were 192 subjects from 284 medical records complying inclusion criteria. Most of the excluded medical records were due to 
inaccessibility or insufficiency data.As shown in Table 1, the highest incidence rate occurred in boys (155 patients, 59.9%) and children with age category of >1–5 years old (78 patients, 40.6%). The clinical features of ALL were shown in Table 2. Pallor was the most common presenting complaint (n172;89.6%), followed 
by fever (n144; 75%). As for clinical findings, hepatomegaly was mostly found (n 153; 79.7%), 
classified into less than 5 cm enlargement group (n117;60.9%), while hemorrhage was mostly seen as skin manifestations (n63;32.8%). Lymph node enlargement was found (n131; 68.2%) with cervical as the most affected area; and Schuffner I-II, as the most common grade of splenomegaly, was detected (n72; 37.5%).Severe anemia (Hb<7 g/dL) was seen (n86; 44.8%), where asleucocytosis was found (n90; 46.9%). Most patients (n98; 51%)
Table 2 Clinical Manifestation of Acute Lymphoblastic Leukemia Patient
Clinical Features
Total
N %Pallor 172 89.6Fever 144 75Hemorrhage     Gum 44 22.9     Epistaxis 27 14.1     Skin 63 32.8     GI Tract 15 7.8     Intracranial 1 0.52     Eye 5 2.6     Urinary Tract 2 1     Others 9 4.7Seizure - -Lymphadenopathy     Cervical 131 68.2     Axillary 22 11.5     Inguinal 36 18.8     Others 3 1.6Hepatomegaly     < 5cm 117 60.9     5–10 cm 34 17.7     >10cm 2 1Splenomegaly     Schuffner I-II 72 37.5     Schuffner III-IV 49 25.5     Schuffner V-VI 2 1     Schuffner VII-VIII - - 
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were classified into severe thrombocytopenia group. Blast cell count >50% acquired from peripheral blood smear examination was also found (n 87; 45.3%) as shown in Table 3.Furthermore, there were 33 samples of 192 ALL patients whose bone marrow aspiration 
(BMA) classification based on FAB was not listed in the medical records. For further 
classification, 2 patients were classified as bilineage leukemia, 2 as early phase leukemia, and 3 others as preleukemia. The most common 
type of ALL based on FAB classification was L2 (n 126; 65.6%), whereas L1 and L3 were found in 21 (10.9%) and 5 (2.6%) patients, respectively.
DiscussionsOur study has shown that acute lymphoblastic 
leukemia (ALL) has been predominantly occurred in boys and children aged >1– 5 years old, consistent with several previous studies in some parts of the world as reported from the USA and Southern China.10,11Acute lymphoblastic leukemia patients 
have various clinical features. Infiltration of blast cells to bone marrow would suppress normal cell proliferation which caused varied presentations in each patient. The earliest manifestations are caused by anemia resulting in pallor and weakness, thrombocytopenia resulting in bleeding, and neutropenia resulting in fever.4 Pallor, hepatomegaly, and fever are found to be the most common presenting clinical manifestation of ALL. This is 
consistent with findings from previous studies that fever, pallor, and hepatosplenomegaly are the main presenting complaints of ALL.12,13
In addition to their infiltration to bone 
Table 3 Laboratory Features of Acute Lymphoblastic Leukemia Patients 
Laboratory Features
Total
N %Hematology Hemoglobin (g/dL)     < 7 86 44.8     7–9.9 73 38     10–10.9 16 8.3
     ≥11 17 8.9Leukocyte(cells/mm3)     <10,000 76 39.6     10,000–20,000 26 13.5     >20,000 90 46.9Thrombocyte (cells/mm3)     <20,000 98 51     20,000-50,000 58 30.2     >50,000-100,000 21 10.9     >100,000-150,000 8 4.2     >150,000 7 3.6Blast cell count     <20% 50 26     20–50% 55 28.6     >50% 87 45.3Bone Marrow Aspirations L1 21 10.9L2 126 65.6L3 5 2.6
Althea Medical Journal. 2019;6(2)
69
marrow, leukemic cells also infiltrate other organs. Spleen, liver, and lymph nodes are the 
most common infiltrated organs.4 As seen in this study where hepatomegaly, splenomegaly, and lymphadenopathy are commonly presented in ALL patients. Similarly, reported in Iran, where main extramedullary symptoms are splenomegaly, followed by hepatomegaly and lymphadenopathy.14Blood examinations in ALL patients will commonly show anemia, thrombocytopenia, and leukocytosis. These abnormalities are due to uncontrolled and excessive lymphoid 
cell proliferation and blast cells infiltrations to bone marrow which caused suppression of normal cell proliferation.4 As shown in this study, most of the patients have severe 
anemia (<7g/dL). These findings are similar to other reports where a large proportion 
of ALL patients are classified for having severe anemia.12,15 Leukocytosis is commonly presented in ALL patients. Similarly to the 
findings in Iran and Brazil, where most patients have leukocytosis.14,16 The majority of the patients have severe thrombocytopenia or decreased platelet count.17 Similarly founded in Brazil where the majority of their ALL patients have thrombocytopenia.15The differentiation process of lymphoid cells is blocked in ALL patients, while their production and proliferation are uncontrolled, 
which result in blast cells findings in peripheral blood smear and bone marrow. ALL can be presumed with blast cells count results >5%, 
however for definite diagnosis of ALL, 20% blast cells or more is needed.4 Based on the result from peripheral blood smear, a large proportion of ALL patients have >50% of blast cells. This result was in sync with another study in Indonesia which reported that in almost ALL cases, peripheral blood smear would present higher blast cells count.17 Based on this study, the majority of the patients 
classified as L2 type. Similarly found in Eastern Iraq and India, where the most dominant type was L2, followed by L1 and L3.12,18The limitation of this study was inaccessible medical record data or incomplete data which caused data to be excluded, resulting in a lower sample population.To conclude, acute lymphoblastic leukemia(ALL) cases predominantly occur in boys and children between 1-5 years old. Pallor, hepatomegaly, and fever are the main presenting clinical features, while the most common laboratory features found in children with ALL are severe anemia, leukocytosis, and severe thrombocytopenia, with blast cells count 
>50%. ALL L2 is the most common type of ALL 
based on FAB classification. By understanding clinical and laboratory manifestation of ALL, this will help in the diagnosis and assessment of severity which, and thus better prognosis and more precise treatment.
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